## TECHNICAL SPECIFICATIONS

| Drug / Excipient | |
|---|---|
| Drug | Sirolimus |
| Drug Dose | 1.27 µg/mm² |
| Drug Carrier | Phospholipid |

| Balloon | |
|---|---|
| Balloon Compliance | Semi-Compliant |
| Sheath Compatibility | 6F, 7F, 8F |
| No. of folds | 3 & 6 |

| Size Available | |
|---|---|
| Balloon Diameter (mm) | 3.00, 4.00, 5.00, 6.00, 7.00, 8.00, 9.00, 10.00, 12.00 |
| Balloon Length (mm) | 20, 40, 60, 80, 100, 120, 150, 200 |
| Catheter Shaft length (cm) | 45 & 90 |

| Delivery System | |
|---|---|
| Guidewire Compatibility | 0.035" OTW |
| Guiding Catheter Compatibility | 7F to 9F |

For Ordering information visit website: www.conceptmedical.com

## OTW DELIVERY SYSTEM




*The above diagram is just an illustration of the product.
Disclaimer: The law restricts these devices to sale by or on the order of a physician. Indications, contradictions, warnings can be found in the product labelling / IFU supplied with each device. For restricted use only in countries where product is registered with applicable health authorities.

CE 1434

Concept Medical

/conceptmedicals
info@conceptmedical.com
www.conceptmedical.com

Scan for more details

CB.BA.MF.BRO.ver.4.0.23-05

Concept Medical

# MagicTouch AVF

## SIROLIMUS COATED PTA BALLOON CATHETER



SIROLIMUS

ARTERIOVENOUS FISTULA AND GRAFT

# MAGICTOUCH AVF



## PROMISING REVASCULARIZATION THERAPY FOR DYSFUNCTIONAL DIALYSIS FISTULA

Magic Touch AVF Designed with Nanolute technology is intended for stenotic lesions of dysfunctional arteriovenous fistula and graft. Nanolute Technology facilitates homogenous drug transfer to the vessel wall. It also avoids chronic inflammation by avoiding the use of polymers.

## MAGIC TOUCH AVF PATENCY RATE


*Adopted from Kennedy SA et al. J Vasc Interv Radiology 2019*
*# Presented at LINC 2021 by Dr. Tang Tjun Yip*

## CLINICAL EVIDENCE

### Kaplan-Meier Survival Estimates of circuit primary patency




### Patency of AVG*




*Presented by Dr. Chieh Suai Tan, at LINC 2021*

# NANOLUTE TECHNOLOGY




## ADVANTAGES OF NANOLUTE TECHNOLOGY

- Facilitates better adhesion of Sirolimus on the balloon surface
- Circumferential coating ensures homogeneous drug delivery
- Effective drug transfer to the deepest layer of the vessel
- Better in-tissue bioavailability of Sirolimus

## SIROLIMUS DISTRIBUTION STUDY

DTF labelled Sirolimus was used to assess the drug distribution following DCB treatment*




*A: Adventitia; EEL: External Elastic Lamina; IEL: Internal Elastic Lamina; L:Lumen; M: Media *EuroIntervention. 2013 May 20;9(1): 148-56*